Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients: A Randomized, Multicenter, Double Blind, Placebo-Controlled Trial (CTOT-47)
Latest Information Update: 28 Feb 2025
Price :
$35 *
At a glance
- Drugs Belumosudil (Primary)
- Indications Lung transplant rejection
- Focus Therapeutic Use
- Acronyms CTOT-47
- 06 Feb 2025 Planned initiation date (estimated date for recruitment of the first subject) changed from 21 Jan 2025 to 28 Feb 2025.
- 06 Feb 2025 Status changed from not yet recruiting to recruiting.
- 10 Jan 2025 Planned initiation date changed from 1 Oct 2024 to 21 Jan 2025.